Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies.

Tara Murty, Jonathan H Lin, Prithvi Mruthyunjaya

Abstract readCase Reports

In one paragraph

Article in American journal of ophthalmology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Tara MurtyByers Eye Institute, Stanford University, Palo Alto, CA, USA.

Jonathan H LinDepartment of Pathology, Stanford University, Palo Alto, CA, USA.

Prithvi MruthyunjayaByers Eye Institute, Stanford University, Palo Alto, CA, USA.

Funding

Stanford Vision Research CoreP30EY026877 · NEI · STANFORD UNIVERSITY · PI Jeffrey L Goldberg · 2017 to 2026

$8.0M

NEI NIH HHS P30 EY026877

6 · The paper itself

Abstract

Purpose: To report two new cases and summarize one case of uveal melanoma following treatment of hematologic malignancies with Bruton's tyrosine kinase inhibitors. Observations: A 71-year Conclusions and Importance: Patients being treated with BTK inhibitors may be at higher risk for the development of uveal melanoma. Based on our findings, we recommend increased surveillance of this patient population for secondary primary or metastatic uveal melanoma. Continued documentation of occurrence in conjunction with research at a molecular and cellular level are warranted to better understand the impact of systemic cancer therapies on secondary malignancies.

Indexed as

Bruton's tyrosine kinase inhibitorHematologic malignancyUveal melanoma

Identifiers

PMID40475129

DOI10.1016/j.ajoc.2025.102345

PMCPMC12138944

What Socratic holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.